# Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

> **NCT01096992** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 51 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Fludarabine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01096992
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-19
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-03-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096992, "Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01096992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*